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Abstract CpG dinucleotides are efficiently methylated in 
vertebrate genomes except in the CpG islands having a high 
C+G content. Methylated CpGs are the single most mutated 
dinucleotide. Sequences urrounding disease causing CpG muta- 
tion sites were analyzed from locus-specific mutation databases. 
Both tetra- and heptanucleotide analyses indicated clear overall 
sequence preference for having pyrimidines 5' and purines 3' to 
the mutated 5-methylcytosine. The most mutated tetranucleo- 
tides are TCGA and TCGG, the former being also a frequent 
restriction and modification site. The results will help in 
elucidating the still controversial mutation mechanism of CpG 
doublets. 
philia A database HAMSTERS [6], somatic point mutations in p53 [7], 
and PAHdb for phenylketonuria [8]. The sequences were taken from 
Genbank. The accession umbers of the sequences are X58957, 
X01179, X02469, and L47800, respectively. GCG program package 
[9] was used for sequence analysis. 
The mutations were analyzed by comparing frequencies of the ob- 
tained mutations to those suggested based on base composition by 
using the ;(2 test to determine the significance of the results. The 
formula for the test is: 
;(z = (O_E)2/E 
where O denotes the observed frequency and E is the expected fre- 
quency. The expectations were calculated by multiplying the frequen- 
cies of mononucleotides. 
Key words: CpG dinucleotide; CpG suppression; 
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I. Introduction 
Vertebrate genomes have a marked overall deficiency of the 
dinucleotide CpG. Most, but not all, cytosines in CpG dinu- 
cleotides of the mammalian genome carry a methyl group 
added by methyltransferase. Methylated CpG dinucleotides 
are known mutational hotspots (for review see [1]). Methyla- 
tion of DNA affects transcription of several genes by prevent- 
ing transcription factors and other proteins from binding. 
CpG sites are also frequently mutated in many cancer types 
[2]. Genome methylation patterns change at different develop- 
ment stages. Although the number of CpG dinucleotides i  
remarkably depleted, about one third of human point muta- 
tions appear in these sites [1]. Spontaneous deamination of 
5-methylcytosine (m5C) to thymine leading to TpG and 
CpA mutations has been suggested to be the reaction mecha- 
nism in CpG alterations [3]. 
Although CpG mutations constitute the single most fre- 
quent mutational effect, the details of the mechanism are still 
unclear. To study the requirements on the DNA we have 
performed an extensive analysis of human CpG doublets 
and flanking nucleotides in hereditary disorders. We found 
clear sequence specificity indicating preference for pyrimidine 
bases 5' and purines 3' to the mutated cytosine. The results 
will prove important in elucidating structural mechanisms of
human diseases and CpG suppression. 
2. Methods 
The mutations were taken from locus-specific mutation databases: 
BTKbase (version 2) for X-linked agammaglobulinemia [4,5], hemo- 
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3. Results and discussion 
CpG doublet is present only at about 20% of its expected 
frequency in vertebrate genomes. The mutated CpG sites were 
studied in four hereditary disorders. We analyzed registries for 
Bruton's tyrosine kinase (BTK) [4,5], factor VIII [6], tumor 
suppressor p53 [7], and phenylalanine hydroxylase (PAH) [8], 
which were chosen based on database size, format and avail- 
ability. General data for the analyzed genes and defects are in 
Table 1. The CpG dinucleotides are remarkably suppressed 
when compared to expected frequencies (Table 1). The highest 
number of CpG sites is in factor VIII gene, where there are 
45% of the expected number. In the three other genes less than 
one third of the calculated sites is present. 
The mutations occur in cytosine C in either the coding or 
noncoding strand giving rise to CpG ~ TpG and CpA transi- 
tions. The analyzed sequence stretches were taken from the 
mutated strand. Altogether 1919 mutations in 94 CpG dou- 
blets were analyzed (Table 1). Only one patient was chosen to 
represent each affected family to avoid bias in calculations. 
The C+G contents (43 57%) and CpG frequencies (1.0-3.6%) 
(Table 1) are typical for human genes. Despite the rarity of 
the CpG doublets, CpG mutations constitute at least one 
third of missense and nonsense mutations in these defects. 
The ratios of CpG mutations in the coding vs. noncoding 
strand have a normal distribution. 
3.1. NCGN sequences 
Analysis of the bases flanking CpG sites indicated that mu- 
tations appear in all the tetranucleotides, although at highly 
variable frequencies (Tables 2 and 3). The most abundant site 
in all four deficiencies i  YCGR (Y denotes pyrimidine and R 
purine). The significance of the distributions was estimated 
with the ;(2 test by comparing the observed mutations to those 
expected based on nucleotide composition. Of the tetranucleo- 
tides, only YCGR is significantly mutated in all four data- 
bases (Table 2). The other NCGN sequences are significantly 
mutated in some disorders, but they are also significantly un- 
derrepresented in some other disorders. Some tetranucleotides 
are even clearly underrepresented in mutations, such as 
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Table 1 
CpG mutations in human disorders 
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BTK FVIII p53 PAH 
C+G (%) 
CpG (%) 
CpG (n) 
Mutations (total) 
Missense+nonsense (n) 
CpG mutations (n) 
CpG sites mutated (%) 
CpG mutations of missense and nonsense mutations (%) 
Ratio (coding vs. noncoding strand) 
46.8 42.6 56.9 47.3 
1.7 1.0 3.6 1.7 
33 71 42 23 
269 541 4499 1162 
124 396 3770 624 
43 201 1437 238 
42.4 43.6 81.0 65.2 
34.7 50.8 38.1 38.1 
1.15 1.83 0.61 0.89 
n denotes number. 
ACGG.  The results propose that the preceding base and 
maybe even the preceding triplet might be somehow corre- 
lated to CpG dinucleotides in mutat ional  hotspots. 
The YCGR sequences are mutated in at least 60% of their 
occurrence in the four studied genes, whereas the other tetra- 
nucleotides have on average markedly fewer mutat ions (Table 
4). It is the most mutated tetranucleotide in all the studied 
disorders. The overall mutabil i ty of the sites is highest in the 
p53 database, presumably because of the large number  of 
total mutations, altogether 4499 patients with 1437 CpG tran- 
sitions. The most abundant  sequences in the mutat ions in all 
four diseases are TCGA and TCGG,  whereas the other two 
YCGR sequences, CCGA and CCGG,  display a more ran- 
dom distr ibution of mutat ions (Table 3). None of the other 
tetranucleotides is significantly mutated in all the studied da- 
tabases. It is interesting that the flanking bases in the inverted 
order, RCGY,  contain mutat ions only in every fourth site 
(Table 4). Despite p53, mutat ions in RCGY tetranucleotides 
are rare or nonexistent except for some single hotspots (Table 
3). 
3.2. NNCGNN sequences 
Because of the clear sequence preference in the CpG con- 
taining tetrapeptides it was tempting to analyze longer se- 
quence stretches as well, to see whether sequence effects 
were more extensive. This was interesting also because of 
the suggested sequence periodicity around CpG sites [10]. 
Analysis of the mutated CpG containing heptapeptides indi- 
cated pronounced sequence specificity for YYCGRR and 
especially YYCGRY,  which both contain the central YCGR 
pattern (Table 5). Both the tetra- and heptanucleotide studies 
indicate obvious sequence preference for neighbors in CpG 
mutations. The mixed occurrence of purines and pyrimidines 
on one or both sides is very rare, and often actually under- 
represented. The overrepresentation at YRCGYR in p53 is 
Table 2 
CpG mutations in NCGN sequences 
NCGN BTK FVIII p53 PAH 
n X 2 n Z 2 n Z ~ n Z 2 
RCGR 8 0.007 54 57.5*** 86 143.6"** 28 1.II 
RCGY 9 0.88 8 5.50* 666 448.0*** 3 29.0*** 
YCGR 26 57.0*** 95 331.1"** 544 302.1"** 164 480.2 **~ 
YCGY 0 5.60* 46 55.9*** 140 92.8*** 43 1.63 
Bold letters indicate overrepresentation and italics underrep- 
resentation,  gives the number of sites. 
The results of the Z 2 test are shown with significance l vel: *P < 0.05; 
**P< 0.01; ***P< 0.001. 
due to a single hotspot. Of  the symmetric sequences YYC- 
GYY  is significantly overrepresented in two diseases, but has 
not been identified at all in one, while in p53 it is significantly 
underrepresented. The largest registry, p53 database, contains 
a significant number  of mutat ions also in the YRCGYR mot i f  
(Table 5). In Btk, only the sequences containing the central 
YCGR mot i f  are significantly mutated, while in factor VIII 
most of the mutat ions appear in the central YCGR,  with 
some other frequently diagnosed sites. Also heptanucleotides 
tend to have purines on one side and pyrimidines on the other 
side of the most mutated CpG dinucleotides. This could mean 
that these stretches are recognized or ignored by some muta- 
tion mechanisms or repair systems, respectively. 
It would have been of interest to study even longer CpG 
containing sequences but the size of databases does not war- 
rant statistical estimations. 
3.3. CNG sequences 
CpNpG sites have been shown to be stably methylated in 
mammal ian cells at low frequency [11]. To see if mutat ion 
patterns are affected by the central base in this triplet the 
distr ibution of mutat ions was analyzed. No sequence prefer- 
ences were noticed when mutat ions in CpG dinucleotides were 
omitted. The incidence of CNG methylat ion outside CpG is 
low and it does not affect mutat ion rates, at least not to a 
degree detectable in the statistical test. 
Table 3 
CpG mutations in tetranucleotides 
NCGN BTK FVIII p53 PAH 
ACGA 0.19 13.3'** 63.2*** 0.47 
ACGC 0.86 1.97 430.*** 
ACGG 3.64 39.3"** 0.72 
ACGT 51.3* * * 4.59 
CCGA 5.92* 3.44 14. 8"** 29.8"** 
CCGC 48.3"** 66.3"** 1.47 
CCGG 4.48* 1042.* * * 
CCGT 0.0001 60.2"** 50.6"** 
GCGA 2.25 47.9"** 55.5"** 0.26 
GCGC 8.69*  87.4*  * 
GCGG 7.13'* 7.31"* 0.0002 
GCGT 0.18 50.6* * 
TCGA 35.8"** 839.9"** 7.79"* 3.32 
TCGC 81.6"** 3.86 
TCGG 19.7"** 9.48** 53.5*** 1976.*** 
TCGT 0.15 0.12 17.7"** 1.89 
The numbers are from the Z z test. 
The significance is as indicated in Table 2. 
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3.4. Mutations in CpG island 
CpG islands are C+G rich regions having a high CpG fre- 
quency. These stretches are clearly undermethylated. CpG 
islands usually appear outside protein coding regions in pro- 
moter regions. The islands are more common among 
housekeeping genes. The gene involved in protein C deficiency 
(entry M11228) contains an island of about 320 nucleotides in 
the middle of the coding region. In the analysis of the data- 
base [12] containing 163 CpG mutations, apparently different 
results were obtained compared to those in Tables 2~,. The 
C+G content is also higher, 62%. Most of the CpG mutations 
are in sites other than YCGR,  which in fact does not contain 
a significant number of mutations. Of the nonsense and mis- 
sense mutations altogether 67% are in CpG dinucleotides. 
However, only three CpG sites were found outside the CpG 
island, and none of them is mutated. Thus, the appearance of 
a CpG island has a profound effect on the mutation pattern 
which is expected ue to biased base composition. It remains 
to be seen if also the CpG island mutations are due to methyl- 
ation, which seems likely. 
Table 5 
CpG mutations in NNCGNN sequences 
NNCGNN BTK VIII p53 PAH 
RRCGRR 25.5*** 56.3*** 0.926 
RRCGRY 0.44 0.034 102.*** 
RRCGYR 13.5*  * 
RRCGYY 17.6"** 0.25 140.*** 7. 73** 
RYCGRR 3.38 80.1"** 10.5"* 0.79 
RYCGRY 1.57 
RYCGYR 111.*** 3.80 
RYCGYY 4.17* 5.17* 
YRCGRR 0.005 9.66** 3Z3'** 0.26 
YRCGRY 0.86 0.013 138.*** 11.1"** 
YRCGYR 298.*** 
YRCGYY 133.*** 
YYCGRR 23.3*  * 34.9*  * 45.9*  * 466.*  * 
YYCGRY 30.2*** 204.2*** 18.5"** 144.1"** 
YYCGYR 96.0*** 114. *** 
YYCGYY 17.3"** 144.*** 40.8*** 
The numbers are from the Z 2 test. 
The significance is as indicated in Table 2. 
The central YCGR sequence is indicated in bold letters. 
3.5. Suppression o f  CpG containing sequences 
CpG dinucleotides have been shown to have a periodicity of 
eight nucleotides in purines in both CpG-poor and -rich re- 
gions of the human genome [10]. CCGG sequences were no- 
ticed to be highly represented on CpG-poor coding regions 
[10]. 
High mutation rates at YCGR sequences, especially TCGA 
(Table 3), would during evolution lead to their suppression 
from coding genes. To test this idea, we analyzed the distribu- 
tion of tetranucleotides in 99 randomly selected human 
mRNA sequences containing 172507 bases and found that 
CCGG is indeed clearly overrepresented 0¢2=82.1"**), consis- 
tent with the previous results [10]. TCGG also appears more 
abundantly than expected (12.4"**), CCGA has the predicted 
frequency, whereas the highly mutated TCGA is significantly 
suppressed (11.5"**). The distribution data show at least in- 
directly the importance of nucleotides flanking mutated CpG 
dinucleotides as well as a relation to the observed mutabilities. 
3.6. Comparison to other studies 
Related observations have been made when studying the 
rate of base substitution in 40 mammalian processed pseudo- 
genes [13]. Relative mutation rates were the highest for 
YCGR stretches in both strands in CpG containing tetranu- 
cleotides. 
Cooper and Krawczak [1] have presented that there is no 
preference for 5' nucleotide in human CpG mutations. Their 
assumption was based on analysis of mutations in the first 
position of codons. The preceding base was suggested to 
have random distribution of the third position base. However, 
when their data were analyzed at the sequence level we found 
a most significant bias in the mutated tetranucleotides. The 
YCGR sequence is clearly overrepresented (~2=11.6"**) in mu- 
Table 4 
Percentage of mutated NCGN sites 
NCGN Btk FVIII p53 PAH 
RCGR 42.9 42.1 77.8 66.7 
RCGY 25 12.5 91.7 25 
YCGR 80 61.1 90 100 
YCGY 0 46.2 63.6 57.1 
tations, while RCGY was underrepresented (3.74). The most 
mutated tetranucleotide s quence was TCGA (29.0"**), which 
alone constitutes 18% of the mutations in the 16 CpG tetra- 
nucleotides. Thus, also their data support our findings. 
3.7. Conclusions 
The results seem to indicate that CpG dinucleotides, 
although appearing in all combinations of flanking bases, 
are much more prone to mutations when there are one or 
more pyrimidines 5' and one or more purines downstream 
of the mutated cytosine. It is interesting that the most fre- 
quent mutation site, TCGA,  has a palindromic sequence, 
which might have functional relevance. TCGA is also a com- 
mon DNA restriction and methylation site. Spontaneous de- 
amination is believed to be the mutation mechanism in 5mC 
sites [3]. Other possible ways are thought to be deficient mu- 
tation repair mechanisms, and recently cytosine methyltrans- 
ferase has been shown to be able to convert 5mC to thymine 
[14]. Also the structure of the DNA might have some local 
alterations (e.g. in grooves) in the presence of one or two 
5mCs in complementary strands and thereby affect e.g. pro- 
tein binding. It remains to be seen what is the general mechan- 
ism, if any, but the inverted repeat of the most frequent mu- 
tation sequence could imply importance of protein-DNA 
interactions. 
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